Featured Research

from universities, journals, and other organizations

Nerve stimulation helps with overactive bladder

Date:
May 30, 2013
Source:
Beaumont Health System
Summary:
New research finds that symptoms of overactive bladder, or OAB, were reduced in those who received tibial nerve stimulation. The three-year results show participants with urinary frequency, urgency and involuntary loss of urine maintained significant improvement in their symptoms.

Electric impulses from a hand-held device travel from the nerves in the ankle to the nerves that control pelvic floor function.
Credit: Image courtesy of Beaumont Health System

Beaumont Health System research finds that symptoms of overactive bladder, or OAB, were reduced in those who received tibial nerve stimulation. The three-year results published in the June issue of The Journal of Urology show participants with urinary frequency, urgency and involuntary loss of urine maintained significant improvement in their symptoms.

Tibial nerve stimulation is a painless procedure that takes place in an outpatient setting. A slim needle electrode is inserted in the ankle, near the tibial nerve. It carries electric impulses from a hand-held stimulator to the nerves in the spinal cord that control pelvic floor function.

Principal investigator Kenneth Peters, M.D., chief of Urology at Beaumont Hospital, Royal Oak and a team of researchers reviewed data of 29 patients who initially responded to 12 weekly neuromodulation system treatments for OAB. Study participants were followed for three years.

Participants received an average of one tibial nerve treatment per month. After 14 weeks of treatment, 77 percent of patients maintained "moderate or marked improvement" in OAB symptoms.

For those who participated in the study, results show frequent trips to the bathroom during the day decreased by nearly 30 percent, or from 12 to 8.7; nighttime trips decreased by almost 40 percent, or from 2.7 to 1.7; and urge incontinence episodes per day decreased by 100 percent.

"This study demonstrates that with ongoing therapy, patients with overactive bladder can have fewer symptoms and can return to daily activity without disruption or embarrassment that is often caused by this condition," says Dr. Peters.

According to the Urology Care Foundation, about 33 million Americans -- men and women -- have OAB. The number of people diagnosed with OAB may be much larger because many people living with this condition don't ask for help; they are embarrassed or unaware of available treatments.


Story Source:

The above story is based on materials provided by Beaumont Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kenneth M. Peters, Donna J. Carrico, Leslie S. Wooldridge, Christopher J. Miller, Scott A. MacDiarmid. Percutaneous Tibial Nerve Stimulation for the Long-Term Treatment of Overactive Bladder: 3-Year Results of the STEP Study. The Journal of Urology, 2013; 189 (6): 2194 DOI: 10.1016/j.juro.2012.11.175

Cite This Page:

Beaumont Health System. "Nerve stimulation helps with overactive bladder." ScienceDaily. ScienceDaily, 30 May 2013. <www.sciencedaily.com/releases/2013/05/130530132535.htm>.
Beaumont Health System. (2013, May 30). Nerve stimulation helps with overactive bladder. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/05/130530132535.htm
Beaumont Health System. "Nerve stimulation helps with overactive bladder." ScienceDaily. www.sciencedaily.com/releases/2013/05/130530132535.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins